Q2 2026 Insmed Inc Earnings Call Transcript
Key Points
- BRINSUPRI's launch continues at a historic pace, with Q2 2026 revenue of $309.2 million, more than doubling the best specialty respiratory launches at this stage.
- BRINSUPRI added approximately 7,000 new patients in Q2, exceeding expectations, with strong payer access (90% approval) and high patient compliance and continuation rates.
- Insmed raised its full-year 2026 BRINSUPRI revenue guidance to $1.25-$1.4 billion and increased peak sales estimates to >$7 billion, reflecting strong demand and market expansion.
- TPIP's open-label extension study in PAH showed sustained efficacy at 12 months, with 65% of patients achieving low-risk status and no new safety signals, supporting its potential as a differentiated prostanoid.
- ARIKAYCE continues to perform well, growing 8% year-over-year, with a supplemental NDA submitted for expansion into all MAC lung disease, potentially opening a larger market.
- The company maintains a strong cash position of $1.2 billion and expects to reach cash flow positivity in 2027 without raising additional capital.
- Early-stage pipeline progress includes FDA clearance for INS1033, a next-generation DPP1 inhibitor, for rheumatoid arthritis, with potential in other indications.
- Combined peak sales estimates for lead assets now exceed $14 billion, up 75% from previous estimates, driven by strong performance and market opportunities.
- BRINSUPRI's gross-to-net is expected to remain in the mid-to-high 20s, which may limit revenue growth despite strong sales.
- The company faces uncertainty in European market access for BRINSUPRI due to budget constraints and lack of willingness to pay for innovation, potentially limiting international revenue.
- TPIP's peak sales estimate of >$6 billion assumes clinical and regulatory success in all four indications, including overcoming orphan drug exclusivity for IPF, which is not guaranteed.
- The company expects to incur $50 million in milestone payments to AstraZeneca in H2 2026, impacting cash flow.
- Increased investments in TPIP Phase III programs, BRINSUPRI DTC advertising, and Japan infrastructure will raise expenses in the second half of 2026.
- BRINSUPRI's peak sales estimate does not include potential upside from comorbid COPD/asthma patients, but this opportunity is still unproven and may take years to materialize.
- The company's cash flow positivity in 2027 is dependent on continued strong revenue growth, which could be affected by competitive or regulatory challenges.
Thank you for standing by, and welcome to the Insmed second-quarter 2026 financial results conference call. (Operator Instructions)
I'd now like to turn the call over to Bryan Dunn, Head of Investor Relations. You may begin.
Thank you, Rob, and good day, everyone. Welcome to Insmed's second-quarter 2026 earnings conference call.
Before we get started, please note that today's call will include forward-looking statements. These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the projections discussed. Please refer to our most recent filings with the Securities and Exchange Commission for a full description of these risk factors.
The information we will discuss on today's call is meant for the benefit of the investment community. It is not intended for promotional purposes, and it is not sufficient for prescribing decisions.
Today's call will feature prepared
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
